Purpose: Renal cell carcinoma is a tumor with unpredictable behavior and defining reliable prognostic factors would be extremely valuable in the clinical setting. Tumor stage, nuclear grade and tumor cell type are the main prognostic clinical parameters available. In this study we evaluated the role of microvascular involvement in the primary lesion for predicting tumor behavior in patients with low stage clinical disease. Materials and Methods: A total of 95 patients with clinically localized renal cell carcinoma (stages T-1-T-2 N-x M-0) underwent radical nephrectomy and/or nephron sparing surgery, and were followed for a median of 45 months. The impact of microvascular tumor invasion on disease progression and its correlation with known pathological outcomes (tumor size, nuclear grade and cell type) were studied. Results: Microvascular tumor invasion was observed in 24 patients (25%), of whom 50% had disease recurrence. Of the 71 patients without microvascular invasion only 4 (6%) showed tumor recurrence. When microvascular invasion was correlated with other histological parameters, a significant statistical association was noted with tumor diameter, perirenal fat invasion, macroscopic extension to the renal vein, nuclear grade, lymph node metastasis and sarcomatous elements in the tumor. Multivariate analysis showed that microvascular invasion and the involvement of regional lymph nodes were independent predictors of disease recurrence. Concerning cancer specific survival, microvascular invasion and perirenal fat infiltration were the only factors related to death. Conclusions: Microvascular invasion is an independent and relevant clinical prognostic parameter for low clinical stage renal cell carcinoma.
机构:
Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USAUniv Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Zisman, A
Chao, DH
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Chao, DH
Pantuck, AJ
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Pantuck, AJ
Kim, HJ
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Kim, HJ
Wieder, JA
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Wieder, JA
Figlin, RA
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Figlin, RA
Said, JW
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Said, JW
Belldegrun, AS
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
机构:
Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USAUniv Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Zisman, A
Chao, DH
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Chao, DH
Pantuck, AJ
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Pantuck, AJ
Kim, HJ
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Kim, HJ
Wieder, JA
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Wieder, JA
Figlin, RA
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Figlin, RA
Said, JW
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA
Said, JW
Belldegrun, AS
论文数: 0引用数: 0
h-index: 0
机构:Univ Calif Los Angeles, Sch Med, Div Urol Oncol, Los Angeles, CA 90024 USA